Presentation is loading. Please wait.

Presentation is loading. Please wait.

Single-Institution, Multidisciplinary Experience with Surgical Resection of Primary Chest Wall Sarcomas  Puja Kachroo, MD, Peter S. Pak, MD, Harpavan.

Published byMarylou York Modified over 5 years ago

Similar presentations

Presentation on theme: "Single-Institution, Multidisciplinary Experience with Surgical Resection of Primary Chest Wall Sarcomas  Puja Kachroo, MD, Peter S. Pak, MD, Harpavan."— Presentation transcript:

1 Single-Institution, Multidisciplinary Experience with Surgical Resection of Primary Chest Wall Sarcomas  Puja Kachroo, MD, Peter S. Pak, MD, Harpavan S. Sandha, MD, Catherine Lee, PhD, David Elashoff, PhD, Scott D. Nelson, MD, Bartosz Chmielowski, MD, PhD, Michael T. Selch, MD, Robert B. Cameron, MD, E. Carmack Holmes, MD, Fritz C. Eilber, MD, Jay M. Lee, MD  Journal of Thoracic Oncology  Volume 7, Issue 3, Pages (March 2012) DOI: /JTO.0b013e df Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Flow chart of the treatment algorithm for chest wall sarcomas at University of California, Los Angeles (UCLA). Number of patients in each group is indicated next to the arrows. Ψ, Four patients with desmoid tumors and one patient with leiomyosarcoma received induction therapy. γ, Induction therapy data were not available for one patient with chondrosarcoma. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e df) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Outcome of all patients with bony and soft tissue sarcomas. The 5-year overall survival (OS) of all patients is 66%. The 5-year disease-free survival (DFS) is 47%. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e df) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Single-Institution, Multidisciplinary Experience with Surgical Resection of Primary Chest Wall Sarcomas  Puja Kachroo, MD, Peter S. Pak, MD, Harpavan."

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
PUBLISH ONLY Journal of Thoracic Oncology

PUBLISH ONLY Journal of Thoracic Oncology
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients  Björn.

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients  Björn.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,
Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Similar presentations

Ads by Google